

A Narrative Review on Increased Prevalence of Cardiovascular Complications Following a COVID-19 Infection: The Risks and Considerations for Effective Management and Practice

Mark A. Faghy^{1,2}, Ruth E. M. Ashton^{1,2}

¹College of Science and Engineering, Biomedical and Clinical Exercise Science Research Theme, University of Derby, Derby, UK, ²Healthy Living for Pandemic Event Protection Network (HL-PIVOT), Department of Physical Therapy, Chicago, IL, USA

Abstract

The COVID-19 pandemic has been one of the largest risks to global population health in recent years, and acute infection and the persistent symptoms of long COVID will likely continue to affect global health for years to come. Long COVID is very complex and impacts multiple systems and organs, resulting in an extensive and undulating presentation of symptoms. COVID-19 has been shown to cause various cardiovascular (CV) injuries following acute infection, with many patients suffering long-lasting impairment. This review article discusses the prevalence of CV complications following an acute COVID-19 infection and considers effective prevention and disease management strategies to help restore functional status and quality of life in patients.

Keywords: Cardiovascular system, COVID-19, pathology, risk factors

INTRODUCTION

The COVID-19 is arguably the greatest threat to population health and well-being since the 1918 Great Influenza epidemic or Spanish Flu. While the pandemic status of COVID-19 has been removed, the threat to population health remains due to sustained and widespread transmission and viral mutations. There can be no doubt that, despite the widespread removal of free testing, mandatory isolation, and social distancing guidelines that COVID-19, through sustained and free transmission, will continue to affect population health and well-being for years to come. While the severity of acute infection has been significantly impacted by the development and widespread rollout of vaccinations, the persistent, episodic, and debilitating condition, known as post-COVID condition or long COVID, remains a very real threat to population health.^[1] The incidence rate for long COVID is estimated to be around one in every ten cases, affecting 10%–30% of nonhospitalized patients, 50%–70% of hospitalized patients,^[2,3] and 10%–12% of vaccinated cases.^[4] Recent estimates report that long COVID affects around 65 million people worldwide,^[5] with contrasting figures provided by data

modeling groups who suggest the number could be as high as 155 million.^[6] To date, there has been no distinct phenotype or risk associated with long COVID cases, and it has been linked with all ages and acute phase disease severities. Accordingly, the data suggest an increased prevalence of long COVID between the ages of 36 and 50 years, and most long COVID cases are in nonhospitalized patients with a mild acute illness,^[7] which is to be expected as these populations represent the majority of overall COVID-19 cases. What is most problematic about long COVID is a complex multisystemic pathophysiology which results in a broad and undulating patient presentation that consists of around 200 symptoms.^[5] In the absence of effective treatments and the development and implementation of fragmented, ineffective, and under-resourced long COVID management services,^[8] long COVID will likely pose sustained pressure on health-care services for years to come.

Address for correspondence: Dr. Mark A. Faghy,
Biomedical and Clinical Exercise Science Research Theme, University of
Derby, Derby 01332, UK.
E-mail: m.faghy@derby.ac.uk

Received: 18-08-2023; **Accepted:** 13-10-2023; **Published:** 29-11-2023

Access this article online

Quick Response Code:



Website:
journals.lww.com/hhmi

DOI:
10.4103/hm.HM-D-23-00038

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Faghy MA, Ashton REM. A narrative review on increased prevalence of cardiovascular complications following a COVID-19 infection: The risks and considerations for effective management and practice. *Heart Mind* 2023;7:202-6.

Increased prevalence of cardiovascular complications, following a COVID-19 infection

While initially characterized as a respiratory illness, wider systemic issues are now acknowledged and well documented. A prospective cohort study of low-risk individuals looked specifically at organ damage in the heart, lungs, liver, kidneys, pancreas, and spleen and demonstrated that 70% of its 201 patients had sustained damage to at least one organ and 29% had multiorgan damage,^[9] which largely remained unchanged 12 months later (59% and 27%, respectively).^[10] Within the context of acute cardiac injury, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause acute myocarditis and pericarditis, with myocardial injury occurring in five of the first 41 patients diagnosed with COVID-19 in Wuhan, China.^[11] This mainly manifested as an increase in the levels of high-sensitivity cardiac troponin I and creatine kinase, indicating acute myocardial injury and mostly resulting in admissions to an intensive care unit.^[12]

As highlighted in the Central Illustration, there is a developing narrative that has been substantiated with a detailed analysis of large data sets, it provides a concerning outlook regarding the substantial increase in long term, risk of cardiovascular disease (CVD), which includes heart attack and stroke, following a SARS-CoV-2 infection.^[13] Further risk factors include cerebrovascular disorders, dysrhythmias, ischemic and nonischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disease.^[14] Wan *et al.*^[15] completed a prospective cohort analysis of patients following a COVID-19 infection between March 2020 and November 2020 and completed an 18-month follow-up on 7,584 patients. During the acute phase, patients with COVID-19 were associated with a significantly higher short-term risk of CVD (hazard ratio [HR]: 4.3, 95% confidential interval [CI]: 2.6–6.9) and all-cause mortality (HR: 81.1, 95% CI: 58.5–112.4) when compared with a control sample ($n = 75,774$). In the postacute phase, 7,139 patients persisted with a higher risk of CVD in the long-term (HR: 1.4, 95% CI: 1.2–1.8) and all-cause mortality (HR: 5.0, 95% CI: 4.3–5.8) compared to a control sample ($n = 71,296$). Further data from Yeo *et al.*^[16] used the Centre for Disease Control National Vital Statistics System to assess the extent and disparity in excess acute myocardial infarction (AMI) and associated mortality during the pandemic, specifically targeting the Omicron (B.1.1.529) variant. The vital statistics system identified 1,522,669 reported AMIs between January 2012 and March 2022. Before the pandemic, AMI-associated mortality demonstrated a reduction in temporal trends over time relative to demographic groups and regions. These trends reverted during the pandemic and demonstrated a significant rise in AMI and mortality among the youngest-aged females and males. On further inspection, the semi-annual percentage change in the youngest and middle-aged groups in AMI-associated mortality increased by 5.3% (95% CI: 1.6%–9.1%) and 3.4% (95% CI: 0.1%–6.8%), respectively. The excess death rate was also increased for the 25–44 years age groups, demonstrating a range from 23% to 34% for the youngest compared to 13%–18% for the oldest age groups.

A recent systematic review^[17] and meta-analysis that yielded 1,244,604 confirmed COVID-19 infections concluded over a mean follow-up period of 8.5 months that the risk of AMI is 4 cases per 1,000 (2 cases per 1,000 in a control cohort). This was associated with an increased incident risk of 1.93 (95% CI: 1.65–2.26). Data produced from the meta-regression also highlighted that the increased risk was also associated with age and sex (male). While the exact pathophysiological mechanisms, risks, and long-term impacts on CV health for COVID-19 and long COVID patients remain largely unknown, the data summarized here and elsewhere are compelling and demonstrates a clear association between COVID-19 and long COVID and an increase in CVD risks and mortality. The increased risk to population health must be addressed as a part of bespoke long COVID and clinical investigations screening patients to detect cardiac damage/abnormalities and inform the development of appropriate and safe methods to manage the condition and, where possible, increase functional status and quality of life.

Considerations for effective prevention, management, and practice

Preventative approaches

The established cause–effect relationship between modifiable lifestyle behaviors and the risk for the premature onset of chronic diseases predisposes physical inactivity and poor diets as two of the most pertinent unhealthy living risk factors for CVD.^[18] While the notion of prevention in the context of an unexpected global pandemic that globally, we were unprepared for seems somewhat quizzical. It has long been understood the role of exercise, healthy eating, and the benefits of engaging and practicing healthy lifestyle behaviors and the protective effects this has on developing chronic disease.^[19] There are conflicting data on the protective benefits of cardiorespiratory fitness^[20] in the prevention of severe acute infection and more chronic issues; however, it is entirely plausible that lifestyle choices surrounding exercise, diet, smoking, and alcohol consumption could offer improved patient outcomes.^[21,22] The caveat to that this is not a uniform response, which is demonstrated by the increasing incidence of long COVID among previously fit, healthy, and even athletic populations.^[23,24]

The complexity and interactive nature of chronic disease is an important consideration in the design, development, and implementation of prevention and optimal management strategies to ensure broad efficacy and effectiveness.^[25] This remains true in the global response to COVID-19, which is equally, if not more, complex in its pathophysiology and epidemiology.^[26] Since the start of the COVID-19 pandemic, various lifestyle factors (i.e., physical activity, alcohol consumption, obesity, smoking, and sleep quality) have been associated with disease severity, patient outcomes, and even mortality.^[27] However, as is the case with many other chronic diseases, there are multidimensional factors that affect patient outcomes. Despite a move toward endemic status, COVID-19 is still very much present in the society. While the impacts of acute infection have largely been attenuated by effective vaccination

Key question


Will the prevalence of CVD and all-cause mortality increase among the COVID and post-COVID populations? Are there effective prevention and management strategies to curtail the risk of cardiac events for these populations?

Key finding

COVID-19 patients report an elevated risk of developing CVD and all-cause mortality which does not diminish with time. The excess death rate is also increased for adults (25–44 years) and older age groups (>65 years). Preventative approaches (e.g., healthy diet) and management strategies (e.g., interdisciplinary approach) should be paid high attention to the COVID and post-COVID populations.

Message for readers

COVID-19 continues to affect global health and well-being via acute infection or long COVID. Multiple CV injuries and disorders have been demonstrated a prolonged damaging effect on the CV system. Comprehensive strategies must be put in place to identify patients to improve functional status and quality of life.



Central Illustration: Short- and long-term effects of COVID-19 on psychological and cardiovascular functions. The prevalence and risk of serious cardiac event and/or mortality following an infection with Sars-CoV-2 has increased at an alarming rate. There is a need to implement effective prevention and management strategies to reduce the risk to population health and wellbeing. CVD=Cardiovascular disease, CV=Cardiovascular, Sars-CoV-2=Severe acute respiratory syndrome coronavirus 2

programs and increased treatment plans, the longer-term effects and risks to population health are ever-present. Therefore, to protect population health and well-being, preventative and proactive approaches will play a significant role if we are to prevent the incidence of long COVID in community settings. The rollout and scaling up of preventive roles, such as with many chronic disease areas, are hindered by a lack of a united showing from leading health-care organizations and political leaders.^[28] Arguably, the most important medical breakthrough in recent times is the COVID-19 vaccination, which undoubtedly saved millions of lives and has also demonstrated a partial (not complete) reduction in the development of long COVID.^[29] However, waning immunity of all current approved COVID-19 vaccinations demonstrates a notable reduction in the protection offered,^[30] therefore requiring repeat vaccinations. However,

access to COVID-19 vaccinations in most countries is not universal and has been limited to those deemed to be at greater risk (e.g., the elderly and those with comorbidities). There is also potential to address health outcomes with other important agendas such as climate emergency and a need for clean air. It is well established that COVID-19 is airborne,^[31] yet access to adequate ventilation within schools, colleges, hospitals, and places of employment where individuals coexist creates an opportunity for heightened and sustained viral transmission.

While these suggestions seem entirely plausible, implementation of these effective preventative measures would require a monumental step change in political agenda and thinking. It makes sense that prevention efforts are prioritized over the need for ongoing management of chronic disease to mitigate

the projected near-and-long-term health consequences and the directly related physical, social, and economic environmental impacts. However, at present, a lack of priority for developing and instilling prevention methods is an additional factor that poses a risk to population health and heaps of pressure on developing effective management strategies.

Management strategies

While the prevention of chronic disease is preferred, in many cases, including in recent times where health-care provision and lifestyle factors have been impeded by COVID-19, there must be a total alignment of political agendas in relation to health and well-being, societal, and economic factors. While prevention is desirable, the stark reality is that this is unlikely, as evidenced by decades of global prevalence data demonstrating continued acceleration.^[32] Therefore, there is an urgent need to implement effective management of CVD that can distinguish between the modifiable and nonmodifiable risk factors, the latter of which now includes COVID-19 infection. Currently, it is not known whether resulting CV damage following a COVID-19 infection is reversible. With a significant increase in CV-related events and associated mortality, an important part of the management process is to obtain a comprehensive and interdisciplinary approach that focuses on the total risk for each patient.^[33] An important component here is the need to make diagnostic screening widely accessible to fully characterize the extent of cardiac injury. Detailed insight from screening methods is imperative to inform the design and implementation of personalized management strategies that seek to consider risk factors collectively rather than individually in a whole risk profile and may be better equipped to reduce long-term risk and symptoms and improve/restore the quality of life. Such an approach should be incorporated into the entire decision-making process that is truly interdisciplinary^[8] and adopts the intricacies of a systems science approach.^[25] Adopting more coordinated approaches could lead to the design and implementation of efficient and effective management services that improve patient outcomes and, more broadly, address a significant and growing burden on health-care services worldwide.

Within the development of management services, it is important to consider both pharmacological and lifestyle approaches. Previous literature has demonstrated the efficacy of pharmacological^[34] and lifestyle^[35] approaches to managing CVD, but the additional dynamic and interrelating nature of COVID-19 could pose additional complexity. Research has demonstrated through *in vivo* and *in vitro* studies that tanshinone IIA and salvianolate Sodium Tanshinone IIA Sulfonate (STS) have numerous cardioprotective effects, which include antioxidative, anti-inflammatory, endothelial protection, myocardial protection, anticoagulation, vasodilation, and anti-atherosclerotic, as well as reducing proliferation and migration of vascular smooth muscle cells, the full detail of which has been expertly summarized by Ren *et al.*^[36] The role of positive lifestyle factors in the management of chronic conditions is of equal importance,^[37]

but to date, these approaches demonstrate little/no success at a population level.

Considerations for practice

The magnitude of increased CV events and mortality following a COVID-19 infection tells a compelling story that, if not addressed, will plague population health and well-being for generations to come. With COVID-19 being normalized within society, our attention must shift from preventive (proactive) approaches to developing detailed and effective management (reactive) services. Arguably, the most important component here is to increase screening and diagnostic processes following a COVID-19 infection to detect CV abnormalities and injury that could pose a risk to health and mortality. Making access to screening and diagnostic tools for a virus that transmits freely within community settings might appear ambitious and, in some sense, not practical or economically viable. However, the long-term risk to global health could have a devastating impact for generations to come. The data are compelling, and the risk to population health must be addressed as a part of bespoke long COVID and interdisciplinary clinical investigations to detect cardiac damage/abnormalities and inform the development of appropriate and safe methods to manage the condition and, where possible, increase functional status and quality of life. To do this effectively, it might be prudent to look beyond and establish collaborative links that sit outside of “usual” clinical practice.^[38,39] This could facilitate the development of (1) avoiding increasing pressure on already stretched health-care services and (2) delivering these approaches at the scale that is and will be required.

CONCLUSION

Despite being in the endemic phase of the pandemic, there is no doubt that COVID-19 will continue to affect the global population for many years to come, whether that be through acute infection or long COVID. Multiple CV injuries and disorders have been documented in patients, demonstrating that COVID-19 can have a prolonged damaging effect on the CV system. With the risk of AMI being twice as likely to occur in those diagnosed with COVID-19,^[17] comprehensive strategies must be in place to screen patients and effectively manage the conditions to improve functional status and quality of life. However, to ease pressure on current health-care systems to develop effective management strategies, governments and policymakers need to prioritize developing and installing prevention methods to reduce conditions that pose a risk to population health.

Author contributions

Mark Faghy and Ruth Ashton developed the idea for the manuscript and worked collaboratively together to write the article. Both authors have given final approval for the current version to be published.

Ethical statement

Ethical statement does not apply to this article.

Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Faghy MA, Owen R, Thomas C, Yates J, Ferraro FV, Skipper L, *et al.* Is long COVID the next global health crisis? *J Glob Health* 2022;12:03067.
- Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, *et al.* Post-COVID conditions among adult COVID-19 survivors aged 18-64 and ≥ 65 years – United States, March 2020–November 2021. *Morb Mortal Wkly Rep* 2022;71:713.
- Ceban F, Ling S, Lui LM, Lee Y, Gill H, Teopiz KM, *et al.* Fatigue and cognitive impairment in post-COVID-19 syndrome: A systematic review and meta-analysis. *Brain Behav Immun* 2022;101:93-135.
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat Med* 2022;28:1461-7.
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21:133-46.
- Hanson SW, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, *et al.* A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. *medRxiv* 2022:2022.05.26.22275532.
- Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, *et al.* Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EclinicalMedicine* 2021;38:101019.
- Faghy MA, Ashton RE, Skipper L, Kane B. Long COVID – Integrated approaches to chronic disease management? *Am J Med* 2023:S0002-7. DOI: <https://doi.org/10.1016/j.amjmed.2023.04.037>.
- Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, *et al.* Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. *BMJ Open* 2021;11:e048391.
- Dennis A, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Eichert N, *et al.* Multi-organ impairment and long COVID: A 1-year prospective, longitudinal cohort study. *J R Soc Med* 2023;116:97-112.
- Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020;17:259-60.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- Sidik SM. Heart-disease risk soars after COVID – Even with a mild case. *Nature* 2022;602:560.
- Abbasi J. The COVID heart-one year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks. *JAMA* 2022;327:1113-4.
- Wan EY, Mathur S, Zhang R, Yan VK, Lai FT, Chui CS, *et al.* Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: A prospective cohort in UK Biobank. *Cardiovasc Res* 2023;119:1718-27.
- Yeo YH, Wang M, He X, Lv F, Zhang Y, Zu J, *et al.* Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic. *J Med Virol* 2023;95:e28187.
- Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. *Int J Cardiol* 2023;372:138-43.
- Pronk NP, Mabry PL, Bond S, Arena R, Faghy MA. Systems science approaches to cardiovascular disease prevention and management in the era of COVID-19: A Humpty-Dumpty dilemma? *Prog Cardiovasc Dis* 2023;76:69-75.
- Arena R, Lavie CJ, Faghy MA, HL-PIVOT Network. What comes first, the behavior or the condition? In the COVID-19 era, it may go both ways. *Curr Probl Cardiol* 2022;47:100963.
- Owen R, Faghy MA, Ashton RE, Ferraro FV. Pre-COVID-19 physical activity status does not protect against reductions in post-COVID-19 symptoms: A correlation relativistic analysis during the lockdown. *Eur J Phys Educ Sport Sci* 2023;9:1-6.
- Arena R, Lavie CJ, HL-PIVOT Network. The global path forward – Healthy living for pandemic event protection (HL – PIVOT). *Prog Cardiovasc Dis* 2021;64:96-101.
- Faghy MA, Arena R, Babu AS, Christle JW, Marzolini S, Popovic D, *et al.* Post pandemic research priorities: A consensus statement from the HL-PIVOT. *Prog Cardiovasc Dis* 2022;73:2-16.
- Phelan D, Kim JH, Elliott MD, Wasfy MM, Cremer P, Johri AM, *et al.* Screening of potential cardiac involvement in competitive athletes recovering from COVID-19: An expert consensus statement. *JACC Cardiovasc Imaging* 2020;13:2635-52.
- Kim JH, Levine BD, Phelan D, Emery MS, Martinez MW, Chung EH, *et al.* Coronavirus disease 2019 and the athletic heart: Emerging perspectives on pathology, risks, and return to play. *JAMA Cardiol* 2021;6:219-27.
- Pronk NP, Faghy MA. Causal systems mapping to promote healthy living for pandemic preparedness: A call to action for global public health. *Int J Behav Nutr Phys Act* 2022;19:13.
- Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. *Postgrad Med J* 2021;97:312-20.
- Li S, Hua X. Modifiable lifestyle factors and severe COVID-19 risk: A Mendelian randomisation study. *BMC Med Genomics* 2021;14:38.
- Faghy MA, Whitsel L, Arena R, Smith A, Ashton RE. A united approach to promoting healthy living behaviours and associated health outcomes: A global call for policymakers and decisionmakers. *J Public Health Policy* 2023;44:285-99.
- Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends Immunol* 2022;43:268-70.
- Chemaitelly H, Abu-Raddad LJ. Waning effectiveness of COVID-19 vaccines. *Lancet* 2022;399:771-3.
- Morawska L, Tang JW, Bahnfleth W, Bluysen PM, Boerstra A, Buonanno G, *et al.* How can airborne transmission of COVID-19 indoors be minimised? *Environ Int* 2020;142:105832.
- Balakumar P, Maung UK, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. *Pharmacol Res* 2016;113:600-9.
- Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: The need for change. *J Hum Hypertens* 2008;22:154-7.
- Dale CE, Takhar R, Carragher R, Katsoulis M, Torabi F, Duffield S, *et al.* The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. *Nat Med* 2023;29:219-25.
- McGregor G, Powell R, Kimani P, Underwood M. Does contemporary exercise-based cardiac rehabilitation improve quality of life for people with coronary artery disease? A systematic review and meta-analysis. *BMJ Open* 2020;10:e036089.
- Ren J, Fu L, Nile SH, Zhang J, Kai G. *Salvia miltiorrhiza* in treating cardiovascular diseases: A review on its pharmacological and clinical applications. *Front Pharmacol* 2019;10:753.
- Arena R, Pronk NP, Laddu D, Whitsel LP, Sallis JF, Lavie CJ, *et al.* Mapping one million COVID-19 deaths and unhealthy lifestyle behaviors in the United States: Recognizing the syndemic pattern and taking action. *Am J Med* 2022;135:1288-95.
- Faghy MA, Arena R, Stoner L, Haraf RH, Josephson R, Hills AP, *et al.* The need for exercise sciences and an integrated response to COVID-19: A position statement from the international HL-PIVOT network. *Prog Cardiovasc Dis* 2021;67:2-10.
- Faghy MA, Ashton RE, Maden-Wilkinson TM, Copeland RJ, Bewick T, Smith A, *et al.* Integrated sports and respiratory medicine in the aftermath of COVID-19. *Lancet Respir Med* 2020;8:852.